Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KarXT relapse-prevention study in psychosis associated with Alzheimer's disease dementia
2022-001515-10Phase 3Active
- Sponsor
- Karuna Therapeutics
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease psychosis (ADP) comparing KarXT randomized withdrawal arm with Placebo randomized withdrawal arm (2 arms). Primary endpoint: Time to relapse. Started Oct 2022; status: active.
02
Drugs
xanomeline
03
Conditions
Alzheimer's disease psychosis (ADP)
Beyond the preview
Go deeper on 2022-001515-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001515-10.